Question

A 62-year-old man with long-standing type 2 diabetes, previous myocardial infarction, and eGFR 55 mL/min/1.73 m² is on metformin and lifestyle therapy. His HbA1c is 7.9%. According to Diabetes Canada, which additional glucose-lowering agent would most appropriately address his cardiovascular risk?

Accepted Answer

Add an SGLT2 inhibitor with proven cardiovascular benefit

Answer

Add a sulfonylurea

Answer

Add a DPP-4 inhibitor

Answer

Add acarbose

Answer

Add basal insulin only

Practice question

A 62-year-old man with long-standing type 2 diabetes, previous myocardial infarction, and eGFR 55 mL/min/1.73 m² is on metformin and lifestyle therapy. His HbA1c is 7.9%. According to Diabetes Canada, which additional glucose-lowering agent would most appropriately address his cardiovascular risk?